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Tenascin-C is a large, multimeric extracellular matrix
protein that is found in a variety of tissues and can have
profound effects on cell adhesion. It is secreted from
cells as a hexamer of six identical chains called a
hexabrachion. Disulfide bonding among tenascin sub-
units mediates intracellular assembly into hexamers.
The amino-terminal assembly domain consists of heptad
repeats and at least six cysteine residues (Cys-64, -111,
-113, -140, -146, -147) that could be involved in multimer-
ization. We have now determined the requirements for
these cysteine residues during hexamer assembly. Our
results show that only Cys-64 is required to form the
hexameric structure. Mutation of Cys-64 to glycine re-
sulted in release of trimer intermediates, which proba-
bly form via the heptad repeats, but no hexamers were
secreted. In contrast, individual or pairs of mutations of
each of the other cysteines had no effect on tenascin
hexamer formation, and inclusion of any other cysteine
mutations along with C64G did not further disrupt the
multimer pattern. However, when all six cysteines were
mutated, monomers were the major extracellular form.
Together, these results show that trimers are an inter-
mediate of tenascin-C assembly and that Cys-64 is essen-
tial for formation of hexabrachions.
Tenascin-C is a large extracellular matrix glycoprotein that
functions during embryogenesis, in the nervous system, and in
tumors (1–4). Tenascin is able to interact with cell surface
receptors including integrins (5–10) and also binds to extracel-
lular matrix proteins such as fibronectin (11, 12). It is secreted
as a large hexabrachion composed of six identical subunits
disulfide-bonded together at their amino termini, yielding a
hexamer as large as 2 MDa. Subunits range in size from 180 to
320 kDa depending on species and on alternative splicing
within the type III repeats. Each subunit consists of an amino-
terminal assembly domain containing heptad repeats and mul-
tiple cysteine residues, a domain of epidermal growth factor
like repeats, fibronectin type III repeats, and a terminal knob
that is homologous to fibrinogen (13–17). Tenascin-C is a mem-
ber of a family of related proteins containing varying numbers
of type III and epidermal growth factor repeats. All family
members, TN-C,1 TN-R, TN-X, and apparently TN-Y (18) are
multimeric but can differ in the numbers of subunits per mul-
timer (2).
The conservation of the amino-terminal assembly domain
among all family members suggests that the multimeric struc-
ture of the tenascin family is important for function. During
tenascin-C biosynthesis, the hexamer is detected very rapidly
without accumulation of intermediates, suggesting that tenas-
cin multimers form by association of nascent polypeptides dur-
ing translation (19). Within the assembly domain reside at
least six cysteine residues that are available for interchain
disulfide bonding in the hexabrachion. Some or all of these
cysteines are likely to function in maintaining the disulfide-
bonded structure. To determine which cysteines are required
for hexamer assembly and to identify any disulfide-bonded
assembly intermediates, we have mutagenized these cysteine
residues and have used a transient expression system based on
COS-1 cells to analyze the requirements for each of these
cysteines and for combinations of cysteines in the formation of
tenascin hexamers. Our results clearly show that only Cys-64
is essential for hexamer formation. Mutant recombinant tena-
scins lacking Cys-64 are assembled into trimers but not hex-
amers, demonstrating that trimers are an intermediate in hex-
amer assembly. In addition, mutation of four cysteine residues
flanking the heptad repeat region does not prevent hexamer
formation, indicating that trimers might form by noncovalent
interactions mediated by the heptad repeats, and these trimer
intermediates are then assembled into hexamers by disulfide
bonding via Cys-64. The disulfide bonds surrounding the hep-
tad repeats probably function to stabilize the trimeric interme-
diate structure.
EXPERIMENTAL PROCEDURES
Cysteine Mutations and Plasmid Preparation—Mouse tenascin
cDNA encoding the large isoform and containing the alternatively
spliced type III repeats A–D was isolated from a bone marrow stromal
cell cDNA library (provided by Dr. Ihor Lemischka, Princeton Univer-
sity) using a human tenascin cDNA probe (20). The tenascin cDNA
encoding the large isoform was inserted into the vector pcDNAI (In-
vitrogen). Restriction and other enzymes used in the construction of
these plasmids were purchased from New England Biolabs or Boeh-
ringer Mannheim. The 59 end of the cDNA is a BamHI site engineered
at the NcoI site at position 125 of mouse tenascin, and a XhoI site was
engineered within the 39-untranslated region at an ApaI site, position
6,222 (17). Polymerase chain reaction (PCR) amplification was used to
generate the small splice variant (TN-S). Two fragments were ampli-
fied, one ending at the 39 end of repeat III5 and the other beginning with
the 59 end of III6. These fragments were ligated together to exclude the
alternatively spliced repeats and then inserted into tenascin cDNA in
pcDNAI, yielding a plasmid encoding TN-S.
All cysteine mutations were made by site-directed mutagenesis using
primers with the desired nucleotide substitutions in conjunction with
appropriate flanking primers to amplify segments of tenascin by PCR.
Below is a list of mutant primers with nucleotide changes underlined.
Each primer contained a nearby restriction site (in italics) that was
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used in combination with a site on the other side of the mutation in the
tenascin cDNA to generate a short fragment for insertion into the TN-S
cDNA in pcDNAI. The pairs of restriction sites are listed at the right
with the first of each pair being the site within the mutant primer. An
asterisk indicates an antisense orientation for the primer.
TNC64G* CCAGATCCACTGAGCCTTGGGA, BstYI to PpuMI
TNC111A GCCGGGCCGCTGGCTGTGCTGCAG, Nci I to ApaLI
TNC113A GCCGGGCCTGTGGCGCTGCTGCAG, NciI to ApaLI
TNCCGG GGGTACAGGCGGTGGCCTCCAACCTGC, RsaI to XcmI
TNC140A* ACCCATGGTGGCCTGCTCCCTT, NcoI to BstYI
TNCGC111 CGCCGGGCCGGTGGCGGTGCTGCAGC, NciI to
ApaLI
PCR amplification with mutant primers was carried out for 30 cycles
under the following conditions: 94 °C, 30 s; 37 °C, 1 min; 72 °C, 30 s. The
DNA sequences of all PCR products were verified using Sequenase
(U. S. Biochemical Corp.).
For construction of multiple mutant combinations, convenient re-
striction sites were used to prepare fragments containing the desired
mutations, and these were ligated into the tenascin cDNA. In those
cases where the complexity of the construction precluded using conven-
ient restriction fragments, mutant tenascin cDNA was used as a tem-
plate for PCR amplification using primers containing additional muta-
tions (from the list above). To confirm the presence of each of the
mutations within the cDNA before transfection, the assembly domain
sequence in pcDNAI was determined for each mutant construct.
Cell Culture, Transfections, and Metabolic Labeling—BHK-HxB.S
cells (provided by Dr. Harold Erickson, Duke University) (21) were
cultured in Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc.) plus 10% fetal calf serum (Hyclone Laboratories). COS-1 cells
(provided by Dr. Ihor Lemischka, Princeton University) were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% calf se-
rum. DEAE-dextran transfections were performed essentially as de-
scribed (22) using 3.3 mg of plasmid DNA with 4 3 105 COS-1 cells/6-cm
dish.
Cells in 35-mm culture dishes were labeled for 24 h with [35S]methi-
onine (NEN Life Science Products) at 25 mCi/ml in Dulbecco’s modified
Eagle’s medium minus methionine supplemented with 10% calf serum
(or fetal calf serum for BHK cells) and unlabeled methionine at one-
tenth the normal concentration. Labeled conditioned medium was col-
lected and stored at 220 °C with protease inhibitors (19).
Immunoprecipitations and SDS-PAGE—Equal volumes of condi-
tioned medium from transfected cells were used to isolate 35S-labeled
normal and mutant tenascins by immunoprecipitation with R759, an
anti-tenascin antiserum (19). Protein samples were separated in SDS-
polyacrylamide gels either reduced with 100 mM dithiothreitol or non-
reduced. Nonreduced samples were separated in 2–5% polyacrylamide
gradient SDS gels with a 2.5% stacking gel. Reduced samples were
electrophoresed in a 5% polyacrylamide-SDS gel. Prestained molecular
mass standards (Sigma), fibronectin isolated from COS-1 cell medium,
and purified laminin-1 (provided by Dr. Peter Yurchenco, Robert Wood
Johnson Medical School, Piscataway, NJ) were used as markers. Two-
dimensional nonreduced/reduced gels were performed as described (23).
After electrophoresis, gels were fixed and stained with Coomassie Bril-
liant Blue to visualize laminin and dried and exposed to a storage
phosphor screen (Molecular Dynamics) for 15–72 h. PhosphorImager
counts per band were quantified using ImageQuant NT software. In
addition, gels were exposed to Kodak XAR-5 film at 280 °C for 2–4
weeks. Autoradiographs were scanned using a UMAX flatbed scanner
with transparency adapter, and scans were used to prepare these
figures.
RESULTS
Construction of Cysteine Mutations and Expression in COS-1
Cells—The amino-terminal assembly domain of tenascin-C
spans the first 150 residues of the protein. Several interesting
structural features within this region include a set of three to
four heptad repeats composed of residues 118–142, cysteines
that can participate in multimerization, as well as two N-
linked glycosylation sites. The locations of six cysteines and of
the heptad repeats are shown in Fig. 1. Mutations of cysteines
at positions 64, 111, 113, 140, 146, and 147 were prepared and
expressed individually or in combinations in the tenascin-C
small isoform (TN-S).
To analyze the multimers formed by tenascin chains lacking
one or more cysteine residues, reasonable quantities of recom-
binant proteins were needed. Therefore, we tested transfected
COS-1 cells for the ability to assemble tenascin into hexamers.
The full-length tenascin cDNA encoding the small splice vari-
ant was inserted into the vector pcDNAI, which has an SV40
origin for increased expression in COS cells with a cytomega-
lovirus promoter to drive tenascin transcription. The
pcDNAI-TN-S plasmid was transfected into COS-1 cells. 24 h
after transfection, cells were metabolically labeled with
[35S]methionine for 24 h, and tenascin was isolated from la-
beled cell-conditioned media by immunoprecipitation with an
anti-tenascin polyclonal antiserum. The level of secretion of
tenascin from COS-1 transfectants was compared with a BHK
cell line expressing HxB.S, the small isoform of human tenas-
cin-C, which has previously been shown by electron microscopy
to secrete recombinant tenascin hexabrachions (21). Fig. 2
shows that transient expression of recombinant tenascin in
COS-1 cells results in secretion of tenascin multimers with an
identical pattern to the HxB.S tenascin. The major band rep-
resents hexamers. A minor band is observed migrating at the
predicted size for trimers, about 700 kDa, as determined by
comparison to laminin-1 (800–850 kDa) and fibronectin (500
kDa). Thus COS-1 cells are able to assemble and secrete tena-
scin hexamers and can be used to examine the behavior of
mutant tenascins.
Effects of Cysteine Mutations on Tenascin Assembly—To de-
termine the roles for the individual cysteines, we have used
PCR-directed mutagenesis to mutate each of the six cysteines
surrounding the heptad repeats. Cysteines were mutated to
either glycine or alanine codons by changing appropriate bases
within oligonucleotide primers used for PCR amplification.
PCR-amplified products were then inserted into the tenascin-C
small splice variant cDNA in the vector pcDNA1 for transient
expression in COS-1 cells. Each mutation was tested individu-
ally except for C146,147G, which was synthesized as a double
mutation. Secreted recombinant tenascins containing each of
the cysteine mutations were electrophoresed under nonreduc-
ing and reducing conditions. All transfectants secreted recom-
binant tenascins that migrated as single bands of about 230
kDa upon reduction (Fig. 3B). In all but one case, the proteins
were present mainly as hexamers (Fig. 3A), and there was no
difference in the multimer patterns between mutants and
TN-S. The one exception is C64G, which was secreted largely as
trimers with variable amounts of dimer-sized material. Two-
dimensional nonreduced/reduced SDS-PAGE was used to show
that these multimers are composed of tenascin subunits (Fig.
3C). Clearly, trimers are a major intermediate in an assembly
pathway that is dependent on Cys-64 for formation of
hexamers.
To determine whether multiple cysteine mutations might
have an effect on tenascin assembly, the mutations were ex-
pressed in combination. C64G in combination with any other
cysteine mutation always gave a pattern of multimers identical
to C64G alone (Fig. 4). The pattern of secreted multimers was
unaffected by the presence of additional mutations. We con-
clude that the inclusion of additional cysteine mutations along
FIG. 1. Amino-terminal assembly domain of tenascin. This dia-
gram shows the position of the three to four predicted heptad repeats
(cross-hatched box) relative to the six cysteine residues analyzed in this
study. Amino acid numbering is according to Spring et al. (14). C,
cysteine.
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with C64G does not further affect the types of multimers that
form.
Two pairs of cysteines, Cys-111, -113 and Cys-146, -147,
flank the heptad repeats. It is possible that these cysteines are
involved in forming disulfide bonds that stabilize tenascin sub-
unit interactions within a trimer intermediate structure. Mu-
tation of all four of these residues might result in a further
reduction in multimer size. A recombinant tenascin cDNA with
mutations in the codons for these four cysteines (43C) was
constructed, and secreted products from transfected COS-1
cells were examined. A number of additional intermediates
appeared consisting of between one and five subunits (Fig. 5).
However, the majority of multimers were composed of four or
more subunits. Therefore, in the absence of disulfide bonds
flanking the heptad repeats, hexamers are still able to form.
Significantly fewer large multimers were seen with the addi-
tion of a fifth mutation at Cys-140 (53C).
Mutation of All Six Cysteines Yields Monomers—As Cys-64 is
required for hexamer formation and the other cysteines partic-
ipate in disulfide bonding to stabilize the hexamer and trimer
intermediates, then mutation of all six cysteines should result
in release of tenascin monomers. Transient expression of a
mutant lacking all six cysteines (63C) yielded monomers (Fig.
5), demonstrating that the hexamers and other multimers
present in 43C and 53C mutants are held together by disulfide
bonds involving Cys-64. Quantification revealed that 80% of
the 63C subunits were in the monomer band. The remainder of
the subunits were present in dimer-sized material, which could
result from disulfide bonds involving the two conserved cys-
teines that lie 14 and 25 residues downstream of Cys-147 at
positions 161 and 172, respectively.
The results of our mutational analyses are summarized in
Table I. Recombinant tenascin-C expressed in either BHK or
COS-1 cells showed the same pattern of multimers, which is
largely hexameric with variable small amounts of trimer-sized
complexes. Each individual mutation, Cys-111 through Cys-
147, yielded the same multimeric pattern as intact tenascin.
Mutation of Cys-64 either alone or in combination with any of
the other cysteine mutations ablated hexamer formation and
resulted in secretion of trimers. With Cys-64 intact, the ab-
sence of cysteines flanking the heptad repeats did not eliminate
hexamers but caused the appearance of monomer, dimer, and
trimer intermediates (4 3 C, 5 3 C). Mutation of all six cys-
teines gave mainly monomers. Together, these results show
that Cys-64 is essential for hexamer formation.
DISCUSSION
The multimeric structure is conserved among the tenascin
family of proteins. Each type of tenascin has a set of heptad
repeats within the amino-terminal assembly domain, and these
are predicted to form a triple coiled-coil structure. We have
analyzed the roles of each of the six cysteines in and around the
heptad repeats and have found that only one cysteine, Cys-64,
FIG. 2. Comparison of tenascin expressed in BHK HxB.S cells
and in COS-1 transfectants. COS-1 cells transiently expressing TN-S
cDNA and BHK HxB.S cells were metabolically labeled with [35S]me-
thionine. Culture media were collected and used for immunoprecipita-
tions with anti-tenascin antiserum. Samples were electrophoresed un-
der nonreducing conditions. Hexamer (H) and trimer (T) bands are
indicated along with molecular mass standards laminin-1 (L, 800–850
kDa) and fibronectin (F, 500 kDa).
FIG. 3. Multimeric structures of individual cysteine mutants.
Labeled cell culture medium for COS-1 cells expressing various cysteine
mutant polypeptides as indicated was used for immunoprecipitation.
Samples were electrophoresed under nonreducing (A) and reducing (B)
conditions. C, nonreduced/reduced two-dimensional gel electrophoresis
was used to show that multimers are composed of tenascin subunits.
Note that the C64G polypeptide does not form hexamers. Hexamer (H),
trimer (T), and dimer (D) locations are marked. Dashes (at right) indi-
cate molecular mass standards: laminin-1 at 800–850 kDa and
prestained molecular weight markers at 600 and 360 kDa.
FIG. 4. C64G tenascin with other cysteine mutations form tri-
mers. The C64G mutation was expressed along with other cysteine
mutations as indicated. Nonreduced samples from immunoprecipita-
tions are shown in comparison to TN-S with hexamer (H), trimer (T),
and dimer (D) locations marked.
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is essential for hexamer formation. Mutation of the other cys-
teines did not prevent the secretion of hexamers, and mutation
of Cys-64 resulted in assembly and secretion of trimers but no
higher multimers. Our results also demonstrate that tenascin
is assembled through a trimer intermediate. Apparently, tena-
scin follows a stepwise process of assembly into hexamers be-
ginning with trimer formation among subunits followed
quickly by linking of two trimers into a hexabrachion.
Previously we had shown that the rapid intracellular assem-
bly of tenascin did not involve detectable intermediates (19).
Only hexamers were found at even the earliest time points,
suggesting cotranslational assembly. Based on our mutational
analyses, we propose that noncovalent trimers are formed via
the heptad repeats as soon as the chains are sufficiently long to
contact each other. Upon further translation elongation, the
trimers would then be assembled into disulfide-bonded hexam-
ers via the essential Cys-64 residue. At some point during this
process, interchain disulfide bonds form between the other
cysteines in this domain and help to stabilize the trimer struc-
ture. However, not all cysteines flanking the heptad repeats
are essential for hexamer or trimer secretion as evidenced by
efficient production, even with multiple cysteine mutations.
Analyses of secreted products composed of 43C and 53C
polypeptides showed a significant level of dimers and mono-
mers. These might represent tenascins that are secreted as
dimers and monomers. An alternative explanation seems more
likely, i.e. that these intermediates actually represent subunits
dissociated from secreted hexamers that are not completely
disulfide-bonded. Tenascin trimers probably form by associa-
tion of three subunits through their heptad repeats. Such non-
covalent coiled-coil interactions could be sufficient for trimer or
hexamer secretion. However, if they are not stabilized by di-
sulfide bonds, the interchain interactions would not withstand
SDS denaturation before SDS-PAGE. Therefore, multimers
lacking stabilizing disulfide bonds among all chains would dis-
sociate into smaller intermediates upon denaturation. In addi-
tion to dimers and monomers, SDS-PAGE of 43C and 53C
mutant tenascins also reveals a subfraction of disulfide-bonded
multimers containing four or more subunits. Covalent interac-
tions between a subset of subunits and involving one other
cysteine in addition to Cys-64 would be sufficient to produce
these higher multimers. Cysteines 161 or 172 downstream of
the heptad repeats could participate in their formation.
Apparently, not all chains are disulfide-bonded together in
intact tenascin, as SDS-PAGE of HxB.S tenascin showed some
multimers consisting of five, four, and three subunits, although
only hexamers were seen by electron microscopy of purified
protein (21). Disulfide bonding at both ends of the coiled-coil is
also not necessary for efficient expression of hexamers. Both
C146,147G and C111,113G mutants had structures indistin-
guishable from native tenascin. Thus, within a population of
normal or mutant tenascins, there can be multimers with in-
terchain disulfide bonds between different numbers and com-
binations of subunits. In intact tenascin, one hexamer can have
six disulfide-bonded chains, whereas another might have only
four or five. This indicates that assembly of specific disulfide
bonding partners is not a fixed process but is stochastic.
Fibrinogen is a major secreted hexameric protein that shows
several structural similarities with tenascin, including coiled-
coil regions and interchain disulfide bridges (24). Additionally,
both have cysteines flanking the coiled-coil region as well as
one or more cysteines near the amino terminus that are impor-
tant for hexamer formation (25, 26). One major difference be-
tween these two proteins is in the roles of the disulfides that
flank the coiled-coil domains. In tenascin, we have shown that
these disulfides are dispensible, and hexamer assembly and
secretion proceed very efficiently without them. In contrast, the
disulfide rings of fibrinogen, particularly the carboxyl-terminal
ring, must be properly formed in order for hexamers to be
secreted (27–29). The differing roles of the disulfides used to
assemble fibrinogen versus tenascin might reflect differences in
the mechanism of assembly of these hexamers. As fibrinogen is
formed from three different gene products (a, b, g), assembly
must occur post-translationally. Therefore, it is possible that
proper alignment of the cysteines is important for proper reg-
ister of the coiled-coil. In addition, the coiled-coil of fibrinogen
is significantly longer than that of tenascin, which could make
molecular register more critical. The complex disulfide bonding
pattern of fibrinogen would also assure that all three chains are
present in the hexamer. As all six tenascin chains are identical,
this is not a concern with this hexamer.
The crystal structures of three- and five-chain parallel
coiled-coils have been reported (30, 31). Comparison of the
positioning of cysteine residues in and around the heptad re-
peats of tenascin to trimeric coiled-coil peptides did not reveal
any obvious orientiation of cysteine side chains that might
predict disulfide bonding partners. In the case of the five-
stranded coiled-coil of cartilage oligomeric matrix protein,
there are two cysteines at the carboxyl terminus of the heptad
repeats, and these form the interchain disulfide bonds (31).
Although these residues lie at the end of the heptad repeats,
they are not part of the coiled-coil structure. In fact, the coiled-
coil is disrupted just before these residues, and they actually
reside within a type III b turn. Thus, other determinants bring
the cysteine residues into a favorable position for disulfide
bridge formation. Using the Multicoils2 program (32) to predict
heptad repeats in the assembly domain of tenascin indicated
2 Internet address: ostrich.lcs.mit.edu/cgi-bin/score.
FIG. 5. Multimers formed with multiple cysteine mutations.
Multimers formed by polypeptides with four (43C 5 C111G, C113G,
C146G, C147G), five (53C 5 C111G, C113G, C146G, C147G,C140A), or
all six (63C) cysteine mutations were analyzed by immunoprecipitation
and nonreduced SDS-PAGE. Fibronectin (FN) dimers at 500 kDa are
shown as a marker. Tenascin hexamers (H), trimers (T), dimers (D),
and monomers (M) are indicated.
TABLE I
Multimer proportions for intact and mutant tenascins
Proteins 4,5,6-mera Trimer Dimer Monomer
HxB.S 111 1 2 2
TN-S 111 1 2 2
C64G (plus/minus other
mutationsb)
2 111 1 2
C111A, C113A, C140A 111 1 2 2
C146,147G or C111,113G 111 1 2 2
43C 111 1 1 1
53C 11 1 1 11
63C 2 2 1 111
a 111, greater than 50%; 11, 25–50%; 1, 10–25%; 2, negligible;
determined using ImageQuant NT software.
b C64G plus and minus other individual mutations or pairs of muta-
tions gave the same pattern of trimers . dimers with no hexamers.
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that Cys-111,-113 and Cys-146,-147 are just outside of the
heptad repeats and not likely to be involved in coiled-coil in-
teractions.3 Therefore, tenascin may resemble cartilage oligo-
meric matrix protein and use structures in addition to a coiled-
coil to bring cysteines into proximity for disulfide bonding.
Whereas tenascin-C is a hexamer, tenascin-R has only been
isolated as trimers or dimers (33), and tenascin-X (34) and
tenascin-Y (18) contain unknown numbers of chains. Compar-
ison of the assembly domains from these three shows that they
are highly conserved. However, there are several differences
that could account for the different numbers of subunits in the
multimers. We have shown that tenascin-C uses Cys-64 to form
hexamers. This cysteine is absent from tenascin-X (35), indi-
cating that this tenascin is probably trimeric. However, a cys-
teine equivalent to Cys-64 (at position 79) is present in tenas-
cin-R (36–38). Why have only trimers and dimers been
observed? In addition to Cys-79, mammalian tenascin-R has an
additional cysteine 48 amino acids upstream (37, 38). Perhaps
these two cysteines can form an intrachain disulfide bond,
preventing them from participating in hexamer assembly and
thus yielding only trimers. This potential mechanism could
also hold for chicken tenascin-R, which has three extra cys-
teines in the first 78 amino acids (36). All have cysteines
flanking the heptad repeats, suggesting a functional role for
these residues. Tenascins probably need to withstand a certain
amount of tension within the extracellular matrix, and disul-
fide bonding around the coiled-coil could serve to prevent un-
raveling of the trimers in these situations. Clearly, nature has
evolved a very complex set of interactions to produce tenascin
family members consisting of different numbers of chains and
has added extra cysteines for stability, probably to strengthen
the hexabrachion for its structural role within the extracellular
matrix.
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